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Abstract
Background: The identification of Mycobacterium-tuberculosis (Mtb) infected
individuals remains a challenge due to an insufficient understanding of immune
responses detected with the current diagnostic tests for latent tuberculosis i.e. the
tuberculin skin test (TST) or IFN–c release assays (IGRAs) and an inability to
distinguish infection stages with current immunologic assays. Further classification
based on markers other than IFN–c may help to define markers of early Mtb
infection.
Methods: We assessed the TST status of Mtb-exposed household contacts at
baseline and at 6 months. Contacts were classified into those with initial positive
TST (TST+); those with baseline negative TST but TST conversion at 6 months
(TST converters, TSTC) and those with persistently negative TST (PTST2). We
assessed their short- and long-term immune responses to PPD and ESAT–6/CFP–
10 (EC) via IFN–c ELISPOTand a multiplex cytokine array in relation to TST status
and compared them to those of TB cases to identify immune profiles associated
with a spectrum of infection stages.
Results: After 1 and 6 days stimulation with EC, 12 cytokines (IFN–c, IL–2, IP–10,
TNF–a, IL–13, IL–17, IL–10, GMCSF, MIP–1b, MCP–3, IL–2RA and IL–1A) were
not different in TSTC compared to TST+ suggesting that robust adaptive
Mtb-specific immune responses precede TST conversion. Stratifying contacts by
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baseline IFN–c ELISPOT to EC in combination with TST results revealed that IP–
10 and IL–17 were highest in the group of TST converters with positive baseline
ELISPOT, suggesting they might be markers for recent infection.
Conclusion: We describe a detailed analysis of Mtb-specific biomarker profiles in
exposed household contacts in a TB endemic area that provides insights into the
dynamic immune responses to Mtb infection and may help to identify biomarkers for
‘at-risk’ populations beyond TST and IGRA.
Introduction
About one–third of the world’s population harbors a latent infection with
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB),
creating a reservoir for the development of active disease and continued
transmission. Mtb infection is characterized by a complex interplay of bacterial
metabolic and replicative stages and host immune responses [1]. Detection of T–
cell sensitization to Mtb antigens has traditionally been used for diagnostic
purposes but has also been associated with the quest to understand the dynamics
of host immunity and protection, which would greatly facilitate development of
optimal therapeutics and vaccines. Current immune based diagnostic methods
include the tuberculin skin test (TST) and IFN–c release assays (IGRA) utilizing
overnight stimulation with dominant Mtb antigens such as ESAT–6/CFP–10
(EC). However, there is a significant discordancy between TST and IGRA, which
is incompletely understood and might be associated with host genetic and/or
environmental factors. Both assays are also currently not able to accurately
discriminate different stages of Mtb infection. Recent studies have addressed
whether quantitative or qualitative differences in immune profiles, gene
expression pattern and functional T–cell signatures between LTBI and TB cases
can be utilized for diagnostic purposes [2–8].
In this regard, has become clear that IFN–c alone is not definitively a marker
for a protective immune response to Mtb [9, 10] and strong IFN–c and TNF–a
responses might even be associated with immune pathology [4]. Conversely, IL–2
secreting central memory cells are associated with latent TB infection (LTBI) and
appear in response to successful TB treatment [11]. The presence of T cells
producing IL–17 during a secondary immune response is thought to be important
for protection against active TB [12], while innate immunity is essential for
protective immunity to Mtb infection prior to development of latency.
Few studies have looked at immune profiles in household contacts based on
longitudinal TST status and have simultaneously assessed TST status and
responses in IGRAs. In Uganda, no differences in innate immune responses were
seen between exposed household contacts that remained TST negative for 1 year
compared to those that converted their TST. However, TST converters had higher
baseline IFN–c responses to Mtb bacilli, culture filtrate protein (CFP) and antigen
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85 B (Ag85B) [13]. Only IFN–c production was assessed and thus the
investigators may have missed key information provided by other cytokines (e.g.
Th1, Th2, Th17). Another study in Pakistan showed no differences in the baseline
levels of IFN–c, TNF–a, IL–10 and IL–6 between TST+ contacts and TST
converters; however, all of their initially TST negative contacts has converted by 6
months; hence no persistently TST negative contacts were studied [14].
As part of the on–going TB case-control studies at the MRC Unit in The
Gambia [15], we analyzed global cytokine profiles using multiplex cytokine arrays
across different infection stages, including TB cases and exposed household
contacts to elucidate whether quantitative or qualitative differences in biomarkers
exist between different infection stages and LTBI phenotypes as defined by TST
and IGRA responses. We used overnight and long-term cultures as it has been
shown in endemic countries that long–term responses can identify persons with
Mtb immune responses not evident in overnight assays and help to explain
discordant results of TST and IGRAs [16–19]. We show that quantitative
differences in cytokine responses exist between infection stages and are dependent
on the length of in vitro stimulation. Most importantly, more than one third of
contacts with initially negative TST converted by 6 month and showed broad
MTB specific immune responses already at enrolment compared to persistent
TST2 contacts. These data add to the understanding of early immune responses to
TB infection and to the interpretation of those immune responses for the
diagnosis of latent TB and may help to identify novel biomarkers for ‘at risk’
populations.
Materials and Methods
Ethics
This study was approved by The Gambia Government/MRC joint Ethics
Committee and the Institutional Review Board of New York University School of
Medicine. Written informed consent was obtained from all participants. All data
was anonymized using a unique Subject Identifier.
Subjects
Adult TB index cases $18 years of age with newly diagnosed smear-positive
pulmonary TB were recruited from major government health centers and the
outpatient and TB clinics at the MRC Unit, The Gambia. All cases had sputum
samples obtained for Ziehl–Neelsen smear microscopy and TB culture. Household
contacts were included if they were aged $18 years of age, lived in the same
compound as the index case for .3 months, and were not treated for TB in the
past year or diagnosed with TB within 1 month of recruitment. After a blood
draw, the TST was carried out with 2 TU (PPD RT23, Statens Serum Institute,
Copenhagen, Denmark) using the Mantoux method. Indurations were recorded
at 48–72 hours. Subjects with a positive TST (induration diameter $10 mm)
Protective Immunity to Tuberculosis
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were offered a chest X-ray and those with symptoms underwent a clinical
assessment. Household contacts with a negative TST at enrolment were invited to
repeat the test after 6 months. TST conversion was defined as a positive test
($10 mm induration) plus an increase in induration of at least 6 mm [20]. Of
initially TST2 contacts, only those with a repeat TST test at month 6 were enrolled
in the biomarker analysis. 2 TST2 contacts showed a reduction of induration
from 8 and 9 mm, respectively, to 0 mm at 6 month and were excluded from the
analysis due to low numbers of contacts with reduction of TST size. All cases and
contacts underwent testing for HIV1/2 (Hexagon HIV; Human Diagnostics
GmbH, Wiesbaden, Germany). Those with a positive screen were excluded from
the biomarker analysis.
Antigens
Pooled sequential, overlapping 15-mer peptides, of ESAT-6 and CFP-10 proteins
were used at a final concentration of 2.5 mg/ml each (Advanced Biotechnology
Centre, Imperial College, UK) [21]. Purified Protein Derivative (PPD) (SSI,
Copenhagen, Denmark) was used at 10 mg/ml. The polyclonal stimulator
Phytohemagglutinin (PHA, Sigma-Aldrich, St. Louis, MO, USA) at 5 mg/ml
served as a positive control and culture medium (RPMI 1640 (Sigma Aldrich)
containing Penicillin (10 IU/mL), Streptomycin (10 mg/mL), L–Glutamine
(2 mM)) served as a negative control.
Preparation of peripheral blood mononuclear cells (PBMC)
PBMC were prepared from heparinized blood using LymphoprepTM (Axis Shield,
Oslo, Norway). Red blood cells were lysed with ACK lysis buffer. All culture assays
were performed on freshly isolated cells.
Ex vivo IFN–c ELISPOT
Ex vivo ELISPOT assays for IFN–c were performed as previously described after
stimulation with ESAT–6/CFP–10 and PPD [22]. Positive test wells were
predefined as containing 30 spot–forming units (SFU)/106 cells more than – and
at least twice as many as – negative control wells [23]. PHA positive controls were
set to 750 SFU/106 cells above negative controls. Negative control wells were
required to have ,100 SFU/106 cells.
Cultured IFN–c ELISPOT
A 10 day cultured ELISPOT was performed as previously described [24]. In brief,
16106 PBMCs were incubated with antigen (EC or PPD) in 500 ml culture
medium with 10% human AB serum (Sigma Aldrich). On days 5 and 7, 250 ml of
medium were replaced with fresh medium containing IL–2 (Chiron, Charlotte,
NC, USA) in a final concentration of 10 IU/ml. On day 9 the cells were washed
three times, re-suspended in 1 ml medium, and rested overnight. On day 10, cells
Protective Immunity to Tuberculosis
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were re-stimulated as described for the ex vivo ELISPOT and processed on day 11.
A positive cultured IFN–c ELISPOT was defined as having .300 SFU/106 cells
above the negative control with at least double the number of the negative control
[24]. The positive PHA controls had to have .1000 SFU/106 cells.
Cell culture for cytokine assays
26105 PBMC/well were placed in culture medium containing 5% AB serum for
overnight stimulation and 10% AB serum for 6 day stimulation; then they were
cultured in 96–well U-bottom tissue culture plates (BD, Franklin Lakes, NJ, USA)
in the presence of EC or medium control. 150 ml of cell-free supernatant was
harvested from each well and duplicates were combined in a new plate and stored
at 220 C˚ until required.
Multiplex bead analysis for cytokine/chemokine production
A 17–plex MILLIPLEXTM MAP Kit (Millipore Corp, Billerica, MA, USA) was used
to measure levels of IFN–c, IL–2, TNF–a, IL–12p70, GMCSF, IL–4, IL–13, IL–10,
IL–2ra, IL–1a, IL–17, MCP–3, MIP–1b, MIP–1a, IL–12p70, CD40L and VEGF in
supernatants obtained on days 1 and 6 according to the manufacturer’s
instructions [25]. The data for MIP–1a, IL–4, IL–12p70, CD40L and VEGF were
not included in our analysis as they were above (MIP–1a) or below (all others) the
limits of standard curve range for the majority of samples in the study population.
The inter–assay coefficient of variation for the quality controls ranged from 11–
23%, similar to described ranges [26]. Cytokine/chemokine levels are expressed in
pg/ml. All laboratory assays were done blinded to the subjects’ group.
Statistical analysis
Household contacts were categorized according to their TST status at screening
and 6 month follow up: TST positive at screening (TST+), TST negative at
screening and positive at 6 month (TST converters5TSTC) and TST negative at
both time points (persistently TST25PTST2). Antigen-specific cytokine/chemo-
kine levels were obtained by subtracting the levels of the un–stimulated well
(negative control) from the antigen–stimulated well. For each analyte, negative
and zero values were set to half the lower limit of detection. To account for
cytokine variance, the geometric mean was calculated for each group (TB cases,
TST+, PTST2, TSTC). For the cytokine/chemokine analyses, the ratio of the
geometric means was calculated between groups. P–values for comparisons
between groups were calculated using the Z–test to allow for unequal variances.
Comparisons were also adjusted for household, age and sex. All listed p–values in
the text are from the adjusted analysis; the unadjusted analysis for the multiplex
assay can be found in the supplementary tables. The demographic characteristics
of the groups were compared using Fisher’s exact test (categorical variables) or
Kruskal–Wallis test (continuous variables). A p–value #0.05 was considered
statistically significant. Statistical analyses were performed using Stata/IC software
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version 11.0 (StataCorp, College Station, TX, USA) and GraphPad Prism software
version 6.0 (Software Mackiev, USA).
Results
Study subjects
23 HIV-negative TB patients and 129 HIV–negative household contacts were
included in our final biomarker analysis. 64 household contacts were TST positive
(TST+) at the time of enrolment. Of the 65 TST negative (TST2) contacts, 26
(40%) showed TST conversion (converters5TSTC) at month 6 while 39 (60%)
remained TST negative (persistently TST25PTST2). There was no difference in
the presence of a BCG scar, BMI index or hematology parameters based on TST
status (Table 1, data for BMI and hematology not shown). However, contacts
with initially positive TST were more likely to sleep in the same bedroom of the
index case than PTST2 (Odds Ratio (OR) 4.3, [95% Confidence Interval (CI)
1.11–24.57], p50.02; Table 1). No statistical significant differences were seen in
the smear grade of index cases between groups, the time to culture positivity or
the prevalence of M. tuberculosis versus M. africanum (Table 1).
IFN–c ELISPOT following ESAT–6/CFP–10 and PPD stimulation
further defines TST phenotypes in household contacts
All subjects had an overnight IFN-c ELISPOT with EC and PPD stimulation
performed at baseline. After stimulation with EC, 32/64 (50%) of TST+ subjects
and 14/65 (22%) of TST2 contacts were ELISPOT+ (ECS+) (OR 3.64 [CI 1.59–
8.51], p,0.001). In relation to the 6 month TST status, the baseline EC ELISPOT
was positive in 9/26 (35%) of TSTC and 5/39 (13%) of PTST2 (OR 3.6 [CI 0.9–
15.6], p50.0625). TST+ and TSTC subjects had significantly higher spot forming
units (SFU) counts following EC stimulation than PTST2 subjects (TST+:
Geometric Mean (GM) [95% confidence interval (CI)]: 24 [CI 14–41] SFU/106
cells; TSTC: 12 [CI 6–25], PTST2: 3.5 [CI 2–5], TST+ vs PTST2: p,0.001, TSTC
vs PTST2: p50.016 (all analyses adjusted for household, sex, gender) while there
was no difference between TST+ contacts and TSTC (Fig. 1A). 21/23 (91%) of TB
cases had a positive response and the GM SFU counts were significantly higher
than for TST+, TSTC and PTST2 (p50.012, p50.002 and p,0.001 respectively;
Fig. 1A).
After overnight stimulation with PPD, 86% of TB cases, 86% of TST+, 88% of
TSTC and 72% of PTST2 contacts had a positive ELISPOT. PTST2 had a
significantly lower GM SFU count compared to TST+ contacts (TST+: 99 [CI 70–
138] SFU/106 cells, PTST2: 39 [CI 23–69], p50.012). PTST2 and TSTC had lower
SFU counts than TB cases but the difference was not significant in the adjusted
analysis (Fig. 1B).
A cultured ELISPOT utilizing both antigens was performed for the last 40
household contacts entering the study: 18 TST+, 8 TSTC and 14 PTST2. In
Protective Immunity to Tuberculosis
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response to EC, TSTC had a higher GM SFU count than both TST+ and PTST2
but the difference did not reach statistical significance after adjusting for age, sex
and household (Fig. 1C). However, TSTC had a significantly higher response to
PPD compared to PTST2 (TSTC: GM 352 [CI 152–816], PTST2: GM 43 [CI 14–
134], p50.014; Fig. 1D).
Interestingly, TST+ contacts with a positive overnight IFN–c ELISPOT had a
significantly larger TST size at enrolment than TST+ contacts with a negative
ELISPOT (Median [IQR]: 18 [10] mm vs 10 [6] mm, p50.002). For the TST
converters, median TST size at 6 months was 18 [6] mm, which was not
statistically different from the median TST size for TST+ contact at enrolment (14
[8] mm). No difference in the TST sizes were seen between TSTC and PTST2 at
the baseline measurement and no difference in the TST size at 6 months between
TSTC with positive versus negative baseline IFN–c ELISPOT, respectively.
Table 1. Demographic, microbiologic and Mtb exposure characteristics of study participants.
Cases (n523) TST+ (n564) TSTC (n526) PTST2 (n539) p–value
Age, median (range) 31 (27–35) 29 (20–38) 29 (23–49) 28 (20–45) ns
Male gender, n (%) 16 (70) 32 (50) 13 (50) 16 (41) ns
Presence of a BCG scar, n (%) 9/20 (45) 35/63 (56) 16/26 (62) 19/39 (49) ns
Baseline TST size, median (min., max,
IQR)
0 (0,16,0) 14 (10,28,9) 0 (0,5,0) 0 (0,5,0) p,0.001
6 month TST size, median (min., max;
IQR)
na na 18 (10,25,6) 0 (0,5,0) p,0.001
Sleeping Proximity to Index Case
Same bedroom, n (%) 17 (27) 3 (11) 3 (8)
Different bedroom, n (%) 29 (45) 15 (58) 16 (41)
Different house, n (%) 18 (28) 8 (31) 20 (51) p50.041*
Smear Grade of Index Case
Grade 1, n (%) 2 (9) 9 (14) 1 (4) 8 (21)
Grade 2, n (%) 9 (39) 27 (42) 12 (46) 15 (38)
Grade 3, n (%) 12 (52) 28 (44) 13 (50) 16 (41) ns
Spoligotype of Index Case where
known
n521 n558 n524 n534
M. tuberculosis, n (%) 11 (52) 35 (60) 19 (79) 27 (79)
M. africanum, n (%) 10 (48) 23 (40) 5 (21) 7 (21) ns
Days to Positivity of Index Case
Cultures
Days, median (IQR) 9 (17) 12 (17) 6.5 (10) 6 (18) ns
* Fisher’s exact test: p50.017 for proximity between TST+and PTST2. ns5not significant; TST+5TST positive; TSTC5TSTconverters; PTST25persistently
TST negative; na5not assessed; IQR5interquartile range.
doi:10.1371/journal.pone.0116268.t001
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Cytokine/chemokine signatures in PTST2 are different from TSTC,
TST+ and TB cases
Cytokine levels measured on day 1 and day 6 of EC stimulation were analyzed for
TB cases, TST+, TSTC and PTST2. The highest responses were seen for IFN–c,
IP–10, TNF–a, MIP–1b and GMCSF for all groups (Fig. 2A; see S1 and S2 Tables
for details and the unadjusted analysis). Most day 6 cytokines levels were higher
than those measured on day 1, except for MIP–1b, TNF–a and IL–2. Of note, IL–
2 levels were very low on day 6 in all groups (Fig. 2A). IFN–c, IL–2, MCP–3 and
IL–13 were significantly higher in TB cases than in PTST2 when adjusted for
household, age and sex (S1 Table). Cases had significantly higher GM of IFN–c
Fig. 1. IFN–c ELISPOT in cases and household contacts in response to stimulation with ESAT–6/CFP–10 (EC) or Purified Protein Derivative (PPD),
at enrolment. Peripheral blood mononuclear cells (PBMC) from TB cases and contacts were stimulated overnight (A and B) or for 6 days (C and D) with EC
(A and C) or PPD (B and D) and an IFN–c ELISPOTwas performed. Horizontal lines represent the geometric mean of the spot forming units (SFU). Contacts
were categorized according to TST scores at baseline and 6 months: TST+5TST positive: TST$10 mm at baseline; TSTC5TST converters: TST,10 mm
at baseline and TST$10 mm plus an increase in induration of at least 6 mm by 6 month; PTST2: persistently TST negative: TST,10 mm at both
time-points. P-values represent comparisons adjusted for household, sex and gender.
doi:10.1371/journal.pone.0116268.g001
Protective Immunity to Tuberculosis
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and TNF–a than TST+ (p,0.05) and higher IP–10 and MCP–3 than TSTC
(p,0.01, S1 Table). The GM of IL–2 was significantly lower in PTST2 as
compared to TST+ and TSTC and the GMs of IFN–c and IL–13 as compared to
TSTC (p,0.05). No significant differences in any cytokine were seen for TST+
compared to TSTC (Fig. 2A, S1 Table). After 6 days in vitro stimulation with EC,
the GM of IP–10 and IL–13 were significantly higher in TB cases compared to
PTST2 (p,0.05). PTST2 subjects also had significantly lower GM of IFN–c,
MIP–1b, IL–2RA and IL–13 levels than TST+ contacts (p,0.05). Compared to
TSTC, PTST2 contacts had lower GM of all analytes except IL–2, TNF–a, IL–10
and IL21A (p,0.05 for MCP–3, IL–13, IL–17; p,0.01 for IFN–c, IP–10, MIP–1b,
Fig. 2. Cytokine/chemokine responses in TB cases and household contacts stratified by TST status after stimulation with ESAT-6/CFP-10 (EC) at
enrolment. Following overnight or 6 day culture of peripheral blood mononuclear cells with EC, supernatants were collected and multiplex cytokine assays
performed. Geometric mean levels are shown (pg/ml) A: Heat map showing geometric mean levels of different analytes after overnight (D1) versus 6 day
(D6) culture in cases and contacts based on TST phenotype. The highest geometric means are shaded in red and the lowest in blue. Contacts were
categorized according to TST scores at baseline and 6 months: TST+5TST positive: TST$10 mm at baseline; TSTC5TST converters: TST,10 mm at
baseline and TST$10 mm plus an increase in induration of at least 6 mm by 6 month; PTST2: persistently TST negative: TST,10 mm at both time–points.
B: Heat map showing geometric mean levels of different analytes after overnight (D1) and 6 day (D6) culture in contacts grouped according to TST status
and baseline EC IFN2c ELISPOT (ECS) results. The highest geometric means are shaded in red and the lowest in blue.
doi:10.1371/journal.pone.0116268.g002
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IL–2RA, GMCSF). No significant differences in any cytokine were seen between
TST+ and TSTC (Fig. 2A, S2 Table).
Responsiveness in the ESAT–6/CFP–10 ELISPOT defines
subgroups of TST converters and persistently TST negative
contacts
We have previously shown that a positive ESAT–6/CFP–10 IFN–c ELISPOT in
TST2 contacts is a strong predictor of subsequent TST conversion [20]. In the
present study, 64% of the TST negative contacts with a positive baseline EC–
ELISPOT converted their TST by 6 month compared to only 33% of those that
were baseline EC–ELISPOT negative (OR 3.6 [CI 0.9–15.6]; not signficant).
Furthermore, TSTC showed strong IFN–c responses to mycobacterial antigens in
the long–term ELISPOT assays as compared to PTST2 subjects. We analyzed
multi-cytokine profiles in these subjects to determine further differences in innate
and adaptive host markers based on TST and EC status. Six groups were defined:
TST+ECS+ (n532), TST+ECS2 (n531), TSTCECS+ (n59), TSTCECS2 (n517),
PTST2ECS+ (n55), PTST2ECS2 (n534) (Fig. 2B, S3 and S4 Tables for details
and the unadjusted analysis). The highest cytokine responses were seen for IFN–c,
IP–10, TNF–a, MIP–1b and GMCSF, especially after 6 days stimulation. However,
the analysis based on ECS status also revealed strong MCP–3 and IL–2RA
responses in ECS+ contacts with positive baseline TST or TST conversion
(Fig. 2B). After overnight stimulation, the GM of IFN–c and IL–2 were
significantly higher in TST+ECS+ and TSTCECS+ than in TST+ECS2, PTST2ECS2
and TSTCECS2 (TSTCECS+ vs TSTCECS2: all p,0.05; TST+ECS+ vs TSTCECS2:
IFN–c: p-0.023; TST+ECS+ vs TST+ECS2: IFN–c: p50.003, all others: p,0.001).
GM levels of IFN–c and IL–2 in PTST2ECS+ were lower than in TST+ECS+ and
TSTCECS+ with only the difference in IFN–c to TSTCECS+ being significant in
the adjusted analysis (p50.02). However, PTST2ECS+ had significantly higher
IL-2 levels than TST+ECS2 and PTST2ECS2 (p#0.002). TSTC with negative ECS
had higher GM IFN–c and IL–2 levels than TST+ECS2 and PTST2ECS2 but
differences were not significant in the adjusted analysis (Fig. 2B, S3 Table).
On day 6, TST+ECS+ and TSTCECS+ had significantly higher GM cytokine/
chemokine levels than TST+ECS2 and PTST2ECS2 and the difference was
significant for all analytes except for IL-13 between TSTCECS+ to TST+ECS2
(p#0.05 for IL–13, IL–17, IL–1A; p#0.01 for TNF–a, IL–10, IL–13 and IL–17;
p#0.001 for all others; Fig. 2B, S4 Table). However, compared to TSTCECS2,
only TNF–a, MCP–3 and IL–10 were significantly higher in TST+ECS+ and
TSTCECS+ as well as IFN–c in TST+ECS+ and IP–10, IL–17 and IL–10 in
TSTCECS+ (p#0.05). TSTCECS+ also had several times higher level of IP–10 and
IL–17 compared to TST+ECS+ (IP–10: p50.037; IL–17: p50.056).
PTST2ECS+ had higher GM of IFN–c, IP–10, MIP–1b, IL–2RA and IL–1A than
TST+ECS2 (p,0.05 for IL–1A, IL–2RA and MIP–1b; p,0.001 for IFN–c, IP-10)
and higher IFN–c and IP–10 than TSTCECS2 (IFN–c: p50.034; IP–10:
p50.001). GMs of IFN–c, IP–10, IL–13, IL–2RA, GMCSF, MIP–1b and IL–1A
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were also higher in this group as compared to PTST2ECS2 (p#0.05 for IL–1A,
IL–13, MIP–1b, GMSCF, p,0.001 for IFN–c, IP–10). Among the ECS2 groups,
TSTCECS2 had significantly higher levels MIP–1b and IL–13 than PTST2ECS2
(p,0.05). Adjusting for sleeping proximity did not change which of the day 1 and
day 6 comparisons were significant (data not shown).
Discussion
To our knowledge, this is the first study to evaluate a panel of Mtb-specific Th1,
Th2, Th17 and innate cytokine/chemokine responses in exposed contacts of TB
index cases stratified by longitudinal TST results and baseline IGRA results.
Importantly, we analyzed cytokine responses in both short and long-term cultures
with Mtb-specific antigens, which revealed important differences between
infection stages. Short-term cultures mainly detect circulating effector memory
response, long-term cultures are thought to reflect central memory cells [19].
One half of exposed contacts had a positive TST at baseline and 40% of the TST
negative contacts showed TST conversion by 6 months. Positive results in the
overnight IFN–c ELISPOT decreased from 50% in TST+ contacts and 33% in TST
converters to only 13% in persistently TST negative contacts.
One of the main findings of our study is that TST converters already showed
broad EC responses at recruitment with no quantitative or qualitative differences
compared to TST+ contacts regardless of the culture time. In contrast to TB cases,
TST converters and TST+ contacts had lower overnight responses in the EC and
PPD ELISPOT assays. TSTC also had lower IP–10 and MCP–3 levels in the
overnight assay while IFN–c and TNF–a levels were lower in TST+ contacts than
in cases. However, on day 6, no significant differences were seen in the adjusted
analysis between both contact groups and cases. These differences between short
and long–term assays in cases versus contacts could be due to a decreased viability
and increased apoptosis of T–cells from TB patients in 6 day cultures as has been
recently described [27, 28] and this was not tested at day 6 in the current study.
However, they are also in line with previous findings that different cell
populations are the source of the cytokines/chemokines such as effector memory
cells in cases versus central memory cells in LTBI [29–31]. For example, Marin
et al found an increase in single and double cytokine-producing CD4+ and CD8+ T
cells in response to PPD in LTBI subjects between day 1 and day 6 and in single
and triple cytokine-producing T cells in response to irradiated Mtb.
Contacts who did not convert their TST had significantly lower IFN–c
responses than TST converters and TST+ contacts in the short-and long–term EC
and PPD ELISPOT assays, lower IFN–c and IL–2 responses in the short term
multiplex assay and lower levels of most cytokines except IL–2 and TNF–a in the
long–term multiplex assay. These results are similar to findings in a Ugandan
study where TSTC had higher IFN–c responses to Mycobacterium tuberculosis
(Mtb), Culture Filtrate (CF) and Antigen 85B (Ag85B) than PTST2 [13].
However, in that study, the baseline IFN–c responses to all 3 antigens were still
Protective Immunity to Tuberculosis
PLOS ONE | DOI:10.1371/journal.pone.0116268 December 30, 2014 11 / 17
significantly lower in TSTC compared to TST+ contacts and only reached similar
levels by 3 months (Ag85B) or even 9–11 months (Mtb, CF). While we were not
able to study longitudinal cytokine responses, our TSTC had strong immune
responses already at enrolment with no differences to TST+ contacts. This
difference might be due to variances in the length and strength of the exposure to
TB cases before enrolment, the different Mtb antigens used for stimulation and/or
methodological differences. Another HHC study in Pakistan found no significant
difference in baseline IFN–c, TNF–a, IL–6 or IL–10 to Culture Filtrate (CF)
between TST+ and TSTC; however the latter had a steeper increase of IFN–c, IL–6
and IL–16 over the 24 months of follow-up compared to our study [14]. Together
these results emphasize that a robust adaptive Mtb specific immune responses
precede TST conversion.
In a previous study in The Gambia, we have shown that a positive recruitment
ELISPOT to EC is a strong predictor of subsequent TST conversion [20]. Indeed,
TST+ contacts and TST converters with a positive EC ELISPOT showed high
positive IFN–c responses after EC stimulation as expected, but also of all the other
cytokines studied. The only difference between TST+ECS+ and TSTCECS+ were
higher IP–10 and IL–17 levels in the latter. IL–17 is a pro–inflammatory cytokine
produced by antigen specific CD4 cells which can enhance a Th1 memory
response but potentially also contribute to lung inflammation by attracting
neutrophils to lung tissue [32, 33]. A recent study showed that 50% of individuals
with LTBI have Mtb specific IL–17 responses while these responses are absent in
TB patients [34]. Similarly, Hur et al found lower IL–17 levels in Malawian TB
patients than in their spouses [35]. In our study, IL–17 responses were generally
low except in the group of TSTCECS+, suggesting that it corresponds to an early
immune-phenotype after recent infection.
Eight percent of contacts with an initial negative TST did not convert the TST
at 6 month despite a positive EC ELISPOT at baseline. Quantitative biomarker
responses to EC in this group were lower compared to TST+ECS+ and TSTCECS+
but the differences were not significant when adjusted for sex, age and household.
Furthermore, all tested cytokines were expressed in this group, including IL–10,
IL–17 and IL–13. Therefore, qualitative immune differences measured in the
peripheral blood in these contacts do not seem to explain the lack of TST
conversion. Quantitative differences could contribute, especially if maintained
over time, and could be related to exposure characteristics or the virulence of the
infecting organism. However, adjusting for sleeping proximity did not alter the
significant results of our analysis. It is more likely that host factors and genetic
determinants contribute to the absence of a DTH response to PPD in the skin
despite positive acquired T–cell responses in the blood. A limitation of this study
was the absence of a follow-up ELISPOT at 6 months, thus we do not know
whether the PTST2ECS+ contacts still had a positive ELISPOT by 6 months or
whether they underwent ELISPOT reversion. This is important to determine in
future studies since it has been shown that patients with initially negative TST but
positive IGRA response are more likely to undergo IGRA reversion over time
[22, 36, 37]. In the overnight EC ELISPOT, PTST2ECS+ contacts had lower SFU
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counts than TST+ECS+ and TSTCECS+. Nevertheless, despite lack of TST
conversion, cytokine levels, particularly IP10, follwoing EC stimulation were
higher than those of TSTCECS2, further supporting the importance of host
factors in Mtb immune responses [38]. Studies in The Gambia and Uganda have
shown that acquired immune responses to secreted Mtb antigens such as ESAT–6
and Ag85 but also the DTH response to PPD are influenced by genetic variance
[39, 40] and this should also be addressed in future studies.
Interestingly, TST+ECS2 contacts had minimal responses to EC across the panel
of cytokines/chemokines evaluated. Furthermore, their cytokines levels were not
different from ECS2 contacts that remained TST negative. In addition, the
TST+ECS2 subjects had a significantly smaller TST size than TST+ECS+ contacts
and lower PPD responses in the ELISPOT, confirming our previous results [21].
The discrepancy between TST and IGRA in these contacts could be related to the
TST response being positive due to BCG vaccination, environmental exposure to
non–tuberculous mycobacteria (NTM) or a remote Mtb infection with loss of
ESAT–6/CFP–10 responsiveness [41, 42]. However, some individuals may lack the
immunological repertoire to respond to EC, thus limiting the sensitivity of the
assay. In that context it is noteworthy that TST converters had equal TST sizes at 6
months regardless of whether the baseline EC ELISPOT was negative or positive.
Limitations of the current IGRAs based on the sole measurement of IFN–c are
evident in the fact that contacts with a negative baseline TST and EC ELISPOT but
TST conversion at 6 month, had significantly higher levels of MIP–1b and IL–13
than EC ELISPOT non-responders who remained TST negative. These cytokine
responses are likely reflecting an early immune response to Mtb exposure/
infection, before the IFN–c response in the EC–ELISPOT or the PPD–DTH
response can be detected. The time to TST conversion after known Mtb exposure
is 3–7 weeks but might be shorter for ex vivo cytokine assays [20]. In contrast, no
difference was seen in the cytokine profiles between TST+ECS2 and PTST2ECS2.
These results emphasize that extended assays and biomarkers other than IFN–c
can increase the sensitivity of blood based tests for the diagnosis of LTBI and help
to characterize the spectrum of TB infection stages. It is likely that PTST2ECS are
truly uninfected. However, it is not possible to exclude the possibility that their
innate immune responses cleared the infection before an acquired response was
elicited or that their acquired immune response does not include responsiveness
to PPD or EC.
The two main limitations to our study were a) a lack of follow-up analysis of
immunological responses, particularly in regards to potential EC reversion and b)
analysis of cytokine profiles at a single cell level which have been shown to help to
elucidate functional signatures correlating with infection stages or protection [7].
A recent review by Prezzemolo et al summarizes current knowledge of CD4+ and
C8+ cell functional signatures in tuberculosis [7]. However, our goal was to
elucidate discordant results between TST and IGRAs whereas most previous
studies use a single assay to define LTBI. Hence, phenotypic and functional
profiling by flow cytometry should be evaluated in future studies.
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In summary, we present detailed biomarker profiles of different TST/IGRA
phenotypes in a TB endemic region that adds to our understanding of Mtb
immune responses in TST converters, persistent negative tuberculin reactors and
contacts with discordant TST and IGRA result. We show that strong immune
responses to EC and PPD are detectable in many contacts prior to TST
conversion. Our results suggest a role for quantitative immune responses in
defining infection stages. In line with previous reports, we detected additional
biomarker responses to Mtb antigens in contacts in long-term assays that would
have been missed in overnight assays and that help to explain some of the
discrepant results observed between TST and IGRAs. However, our results also
suggest that the observed variability and discordance of in vitro assays versus
dermal DTH responses cannot be fully eliminated by studying cytokines other
than IFN-c or using long-term stimulation assays [43]. A better understanding of
the contribution of host genetics to anti-mycobacterial immune responses might
help to find improved markers for latent TB in different contact groups.
Furthermore, it is imperative to understand whether and how the described
phenotypes differ in their clinical course and risk for active TB.
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S1 Table. Cytokine/chemokine responses of cases and contacts after 1 day
stimulation with ESAT–6/CFP–10 (EC). The geometric mean (GM) levels are
shown in pg/ml and the ratio of the geometric mean levels is compared to TST+
contacts. P–values are shown for the unadjusted analysis and after adjustment for
household, sex and age. ns5not significant5p.0.05. TST+5TST positive at
baseline; TSTC5TST converters; PTST25persistently TST negative.
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TSTC5TST converters; PTST25persistently TST negative.
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S3 Table. Cytokine/chemokine responses of contacts stratified by TST and
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significant. ECS+5positive EC ELISPOT; ECS25negative EC ELISPOT;
TST+5TST positive at baseline; TSTC5TST converters; PTST25persistently TST
negative.
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Protective Immunity to Tuberculosis
PLOS ONE | DOI:10.1371/journal.pone.0116268 December 30, 2014 14 / 17
S4 Table. Cytokine/chemokine responses of contacts stratified by TST and
ESAT-6/CFP-10 ELISPOT (ECS) results after 6 day stimulation with ESAT–6/
CFP–10. The geometric mean (GM) levels are shown in pg/ml and the ratio of the
geometric mean levels is compared to TST+ECS2 contacts. P–values are shown for
the unadjusted analysis and after adjustment for household, sex and age. ns5not
significant; ECS+5positive EC ELISPOT; ECS25negative EC ELISPOT;
TST+5TST positive at baseline; TSTC5TST converters; PTST25persistently TST
negative.
doi:10.1371/journal.pone.0116268.s004 (DOCX)
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